SequelSEC

VERTEX PHARMACEUTICALS INC / MA VRTX

Pharmaceutical Preparations · CIK 0000875320 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$12.59B
Fiscal year ended 2026-06-30
Operating income
$4.78B
Fiscal year ended 2026-06-30
Free cash flow
$3.80B
Fiscal year ended 2026-06-30

VERTEX PHARMACEUTICALS INC / MA (VRTX) reported revenue of $12.59B and net income of $4.41B for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from VERTEX PHARMACEUTICALS INC / MA’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

VERTEX PHARMACEUTICALS INC / MA income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$12.59B
Cost of revenue$1.76B
Gross profit$10.82B
Operating income$4.78B
Net income$4.41B
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax income$5.27B
Income tax expense$869.30M
Diluted EPS$17.17
Selling, general & administrative$2.01B
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

VERTEX PHARMACEUTICALS INC / MA balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$6.14B
Total assets$27.42B
Current assets$12.54B
Total liabilities$7.18B
Current liabilities$3.94B
Total equity incl. NCI$20.25B
Temporary (mezzanine) equityUnavailable
Inventory$1.77B
Accounts receivable$2.13B
Goodwill$1.09B
Long-term debtUnavailable
Accounts payable$429.50M

Cash flow

VERTEX PHARMACEUTICALS INC / MA cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$4.29B
Capital expenditures$496.80M
Investing cash flow-$882.80M
Financing cash flow-$2.20B
Net change in cash$1.17B
Stock-based compensation$689.10M
Common dividends paidUnavailable
Common share repurchases$2.01B
Depreciation & amortization$222.10M

Derived

VERTEX PHARMACEUTICALS INC / MA derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$3.80B
Gross margin86.0%
Operating margin38.0%
FCF margin30.2%
SBC / revenue5.5%
Current ratio3.19x
Revenue YoY growth10.2%
Net margin35.0%
R&D / revenueUnavailable
CapEx / revenue3.9%
Long-term debt / equityUnavailable
Effective tax rate16.5%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VRTX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-02-13View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.